ChromaDex Corp., along with the University of Mississippi, yesterday announced the university has granted the company the exclusive worldwide patent rights for pterostilbene as a potential new therapeutic.
ChromaDex’s patented pTeroPure® is a pure form of pterostilbene, a compound found in blueberries and believed to have numerous health benefits, including for use as an anxiolytic or anti-anxiety agent.
Research conducted by the University of Mississippi School of Pharmacy has demonstrated that pterostilbene may have anxiolytic activities by signaling pathways in the area of the brain believed to play a role in anxiety.
The patent award is in line with ChromaDex’s strategy of expanding its intellectual property and boosting its pTeroPure product portfolio to seek out ways to enter new markets.
“Adding the anxiolytic indication to our existing patent portfolio around pTeroPure allows us to capitalize on new product opportunities that we can pursue independently or with partners looking to differentiate their own products,” ChromaDex President William Spengler stated in the press release. “ChromaDex will continue to seek partners such as the University of Mississippi so as to capture advancements in natural product research that will allow us to provide the marketplace with innovative proprietary ingredients.”
ChromaDex has already licensed two patents from the University of Mississippi regarding pterostilbene as a means to reduce blood lipoprotein levels, as well as for pterostilbene’s effect on oxidative stress and cognition.
For more information visit www.chromadex.com